Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation

Uncontrolled complement activation contributes to multiple immune pathologies. Although synthetic compstatin derivatives targeting C3 and C3b are robust inhibitors of complement activation, their physicochemical and molecular properties may limit access to specific organs, development of bifunctiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Garlich, Joshua, Cinier, Mathieu, Chevrel, Anne, Perrocheau, Anaëlle, Eyerman, David J., Orme, Mark, Kitten, Olivier, Scheibler, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946527/
https://www.ncbi.nlm.nih.gov/pubmed/35327625
http://dx.doi.org/10.3390/biom12030432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946527/
https://www.ncbi.nlm.nih.gov/pubmed/35327625
http://dx.doi.org/10.3390/biom12030432

Ejemplares similares